Report cover image

Asia-Pacific Liver Fibrosis Treatment Market

Publisher Data Bridge Market Research
Published Apr 01, 2025
Length 350 Pages
SKU # DAABD20406799

Description

Asia-Pacific liver fibrosis treatment market is expected to reach USD 9.93 billion by 2032 from USD 3.77 billion in 2024, growing at a substantial CAGR of 12.9% in the forecast period of 2025 to 2032.

Market Segmentation:
Asia-Pacific Liver Fibrosis Treatment Market, By Treatment Type (Medication and Surgery/Therapy), Stages ( F2, F1, F3, and F4), Indication (Non-Alcoholic Steatohepatitis (NASH), Hepatitis B & C-Induced Fibrosis, Alcoholic Liver Disease (ALD), Autoimmune Liver Diseases, Genetic Disorders, and Others), Gender(Male and Female), End User (Hospitals, Specialty Clinics, Clinics, Ambulatory and Research Centers, and Others), Distribution Channel (Direct Tender and Retail Sales), Country (China, Japan, India, Australia, South Korea, New Zealand, Singapore, Thailand, Philippines, Malaysia, Indonesia, Vietnam, Taiwan, and Rest of Asia-Pacific) - Industry Trends & Forecast To 2032
Overview of Asia-Pacific Liver Fibrosis Treatment Market Dynamics:

Driver

• Increasing Prevalence of Liver Diseases
Restraint

• Limited Awareness of Liver Diseases
Opportunity

• Progress in Pipeline Products for Liver Fibrosis Treatment
Market Players:

The key market players operating in the Asia-Pacific liver fibrosis treatment market are listed below:

• Gilead Sciences, Inc.
• AbbVie Inc.
• Merck & Co., Inc.
• Novartis AG
• Intercept Pharmaceuticals, Inc.
• F. Hoffmann-La Roche Ltd
• Abbott
• La Renon Healthcare Pvt. Ltd.
• GENFIT SA
• Madrigal Pharmaceuticals
• Aligos Therapeutics
• Pfizer Inc.
• Enanta Pharmaceuticals, Inc.
• Bristol-Myers Squibb Company
• Vertex Pharmaceuticals Incorporated
• Takeda Pharmaceutical Company Limited
• Hepion Pharmaceuticals
• Echosens
• Galectin Therapeutics, Inc.
• Conatus Pharmaceuticals
• Tvardi Therapeutics
• Viking Therapeutics
• Calliditas Therapeutics AB
• Novomedix
• Galecto Biotech
• Pilant Therapeutics, Inc.
• Sagimet Biosciences
• Gyre Therapeutics, Inc.
• Akero Therapeutics, Inc.
• CureVac SE
• Novo Nordisk A/S
• Ipsen Pharma
• AdAlta Limited
• Alentis Therapeutics AG

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.

Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.

Table of Contents

350 Pages
1 Introduction
1.1 Objectives Of The Study
1.2 Market Definition
1.3 Overview Of The Asia-pacific Liver Fibrosis Treatment Market
1.4 Currency And Pricing
1.5 Limitations
1.6 Markets Covered
2 Market Segmentation
2.1 Markets Covered
2.2 Geographical Scope
2.3 Years Considered For The Study
2.4 Dbmr Tripod Data Validation Model
2.5 Multivariate Modelling
2.6 Treatment Type Lifeline Curve
2.7 Primary Interviews With Key Opinion Leaders
2.8 Dbmr Market Position Grid
2.9 Market End User Coverage Grid
2.10 Vendor Share Analysis
2.11 Secondary Sources
2.12 Assumptions
3 Executive Summary
4 Premium Insights
4.1 Pestal Analysis
4.2 Porters Five Forces Analysis
4.2.1 Liver Transplantation Volume And Their Cost For Liver Fibrosis By Country
4.2.2 Endoscopic & Minimally Invasive Procedures For Liver Fibrosis: Volume And Cost By Country
4.2.3 Partial Hepatectomy (Liver Resection) Cost By Country
4.2.4 Cell-based Therapy Cost For Liver Fibrosis Treatment By Country
4.3 Epidemiology
4.3.1 Incidence Of All By Gender
4.3.2 Treatment Rate
4.3.3 Treatment Rate
4.3.4 Drug Adherence And Therapy Switch Model
4.3.5 Patient Treatment Success Rates
4.4 Marketed Drug Analysis
4.5 Demographic Trends: Impacts On All Incidence Rates
4.5.1 Patient Flow Diagram
4.5.2 Key Pricing Strategies
4.5.3 Key Patient Enrollment Strategies
5 Asia-pacific Liver Fibrosis Treatment Market: Regulations
6 Market Overview
6.1 Drivers
6.1.1 Increasing Prevalence Of Liver Diseases
6.1.2 Rising Consumption Of Alcohol
6.1.3 Rising Liver Transplantation Rates
6.1.4 Growing Incidence Of Non-alcoholic Fatty Liver Disease (Nafld) & Nash
6.2 Restraints
6.2.1 Limited Awareness Of Liver Diseases
6.2.2 Regulatory Challenges
6.3 Opportunities
6.3.1 Emerging Technologies And Advanced Treatments In Liver Fibrosis Management
6.3.2 Progress In Pipeline Products For Liver Fibrosis Treatment
6.3.3 Strategic Mergers And Acquisitions Among The Key Players
6.4 Challenges
6.4.1 Lack Of Effective And Approved Anti-fibrotic Drugs
6.4.2 High Cost Of Treatments In Liver Fibrosis Care
7 Asia-pacific Liver Fibrosis Treatment Market, By Treatment Type
7.1 Overview
7.2 Medication
7.2.1 Antiviral Agents
7.2.1.1 Velpatasvir/Sofosbuvir
7.2.1.2 Tenofovir
7.2.1.3 Ledipasvir/Sofosbuvir
7.2.1.4 Sofosbuvir
7.2.1.5 Entecavir
7.2.2 Antifibrotic Agents
7.2.2.1 Obeticholic Acid
7.2.2.2 Tgf-β Inhibitors
7.2.2.3 Connective Tissue Growth Factor (Ctgf) Inhibitors
7.2.2.4 Lysyl Oxidase-like 2 (Loxl2) Inhibitors
7.2.2.5 Others
7.2.3 Anti-inflammatory Drugs
7.2.3.1 Corticosteroids
7.2.3.1.1 Prednisone
7.2.3.1.2 Dexamethasone
7.2.3.2 Tumor Necrosis Factor (Tnf) Inhibitors
7.2.3.2.1 Infliximab
7.2.3.2.2 Etanercept
7.2.3.3 Interleukin (Il) Inhibitors
7.2.3.3.1 Il-6 Inhibitors (Tocilizumab)
7.2.3.3.2 Il-1 Inhibitors (Anakinra)
7.2.4 Immunosuppressants
7.2.4.1 Mycophenolate Mofetil
7.2.4.2 Tacrolimus
7.2.4.3 Cyclosporine
7.2.5 Marketed Drugs
7.2.5.1 Velpatasvir/Sofosbuvir
7.2.5.2 Tenofovir
7.2.5.3 Ledipasvir/Sofosbuvir
7.2.5.4 Obeticholic Acid (Oca)
7.2.5.5 Sofosbuvir
7.2.5.6 Pirfenidone
7.2.5.7 Others
7.2.6 Pipeline Drugs
7.2.7 Branded Drugs
7.2.7.1 Epclusa
7.2.7.2 Viread And Vemlidy
7.2.7.3 Ocaliva
7.2.7.4 Harvoni
7.2.7.5 Sovaldi
7.2.7.6 Baraclude
7.2.7.7 Actos
7.2.7.8 Others
7.2.8 Generic Drugs
7.2.9 Oral
7.2.10 Parenteral
7.2.11 Others
7.3 Surgery/Therapy
7.3.1 Liver Transplantation
7.3.2 Orthotopic Liver Transplant (Olt)
7.3.3 Living Donor Liver Transplant (Ldlt)
7.3.4 Split Liver Transplantation
7.3.5 Domino Liver Transplant
7.3.6 Endoscopic & Minimally Invasive Procedures
7.3.6.1 Endoscopic Variceal Ligation (Evl)
7.3.6.2 Transjugular Intrahepatic Portosystemic Shunt (Tips)
7.3.6.3 Liver Ablation Procedures
7.3.6.3.1 Radiofrequency Ablation (Rfa)
7.3.6.3.2 Microwave Ablation (Mwa)
7.3.7 Partial Hepatectomy (Liver Resection)
7.3.7.1 Segmental Resection
7.3.7.2 Lobectomy
7.3.7.3 Wedge Resection
7.3.8 Cell-based Therapy
7.3.8.1 Stem Cell Therapy
7.3.8.1.1 Mesenchymal Stem Cells (Mscs)
7.3.8.1.2 Hematopoietic Stem Cells (Hscs)
7.3.8.2 Gene Therapy
7.3.8.2.1 Crispr-based Liver Regeneration
7.3.8.2.2 Hepatic Stellate Cell (Hsc) Inhibitors
7.3.8.2.3 Sirna-based Therapies
7.3.8.2.4 Hepatocyte Apoptosis Inhibitors
7.3.8.2.4.1 Oxidative Stress Inhibitors
7.3.8.2.4.2 Emricasan
7.3.8.2.4.3 Pentoxifylline
7.3.8.2.4.4 Losartan
7.3.8.2.4.5 Methyl Ferulic Acid
7.3.8.2.4.6 Others
7.4 Others
8 Asia-pacific Liver Fibrosis Treatment Market, By Stages
8.1 Overview
8.2 F2
8.3 F1
8.4 F3
8.5 F4
9 Asia-pacific Liver Fibrosis Treatment Market, By Indication
9.1 Overview
9.2 Non-alcoholic Steatohepatitis (Nash)
9.3 Hepatitis B & C-induced Fibrosis
9.3.1 Chronic Hepatitis B Virus (Hbv) Fibrosis
9.3.2 Chronic Hepatitis C Virus (Hcv) Fibrosis
9.4 Alcoholic Liver Disease (Ald)
9.5 Autoimmune Liver Diseases
9.5.1 Autoimmune Hepatitis (Aih)
9.5.2 Primary Biliary Cholangitis (Pbc)
9.5.3 Primary Sclerosing Cholangitis (Psc)
9.6 Genetic Disorders
9.6.1 Hemochromatosis
9.6.2 Wilson’s Disease
9.6.3 Alpha-1 Antitrypsin Deficiency
9.7 Others
10 Asia-pacific Liver Fibrosis Treatment Market, By Gender
10.1 Overview
10.2 Male
10.2.1 40-55 Years
10.2.2 Above 55 Years
10.2.3 Below 40 Years
10.3 Female
10.3.1 Above 55 Years
10.3.2 40-55 Years
10.3.3 Below 40 Years
11 Asia-pacific Liver Fibrosis Treatment Market, By End User
11.1 Overview
11.2 Hospitals
11.2.1 Public Hospitals
11.2.2 Private Hospitals
11.3 Specialty Clinics
11.3.1 Hepatology Clinics
11.3.2 Gastroenterology Clinics
11.4 Clinics
11.5 Ambulatory And Research Centers
11.6 Others
12 Asia-pacific Liver Fibrosis Treatment Market, By Distribution Channel
12.1 Overview
12.2 Direct Tender
12.2.1 Retail Sales
12.2.1.1 Hospital Pharmacy
12.2.1.2 Retail Pharmacy
12.2.1.3 Online Pharmacy
13 Asia-pacific Liver Fibrosis Treatment Market, By Region
13.1 Overview
13.2 Asia-pacific
13.2.1 China
13.2.2 Japan
13.2.3 India
13.2.4 South Korea
13.2.5 Australia
13.2.6 Singapore
13.2.7 Thailand
13.2.8 Indonesia
13.2.9 Malaysia
13.2.10 Taiwan
13.2.11 New Zealand
13.2.12 Philippines
13.2.13 Vietnam
13.2.14 Rest Of Asia-pacific
14 Asia-pacific Liver Fibrosis Treatment Market: Company Landscape
14.1 Company Share Analysis: Global
15 Swot Analysis
16 Company Profiles
16.1 Gilead Sciences, Inc.
16.1.1 Company Snapshot
16.1.2 Revenue Analysis
16.1.3 Company Share Analysis
16.1.4 Product Portfolio
16.1.5 Recent Development/News
16.2 Abbvie, Inc.
16.2.1 Company Snapshot
16.2.2 Revenue Analysis
16.2.3 Company Share Analysis
16.2.4 Product Portfolio
16.2.5 Recent Development
16.3 Merck & Co, Inc.
16.3.1 Company Snapshot
16.3.2 Revenue Analysis
16.3.3 Company Share Analysis
16.3.4 Product Portfolio
16.3.5 Recent Development
16.4 Novartis Ag
16.4.1 Company Snapshots
16.4.2 Revenue Analysis And Segmented Analysis
16.4.3 Company Share Analysis
16.4.4 Product Portfolio
16.4.5 Pipeline Product Portfolio
16.4.6 Recent Development
16.5 Intercept Pharmaceuticals, Inc.
16.5.1 Company Snapshots
16.5.2 Company Share Analysis
16.5.3 Revenue Analysis And Segmented Analysis
16.5.4 Product Portfolio
16.5.5 Pipeline Product Portfolio
16.5.6 Recent News
16.6 Abbott
16.6.1 Company Snapshot
16.6.2 Revenue Analysis
16.6.3 Product Portfolio
16.6.4 1.1.5 Recent Development
16.7 Aligos Therapeutics
16.7.1 Company Snapshot
16.7.2 Revenue Analysis
16.7.3 Product Portfolio
16.7.4 Recent Development
16.8 Alniche Life Sciences Pvt. Ltd.
16.8.1 Company Snapshot
16.8.2 Product Portfolio
16.8.3 Recent Development
16.9 Alentis Therapeutics Ag
16.9.1 Company Snapshot
16.9.2 Pipeline Product Portfolio
16.9.3 Recent Development
16.10 Adalta Limited
16.10.1 Company Snapshot
16.10.2 Revenue Analysis
16.10.3 Pipeline Product Portfolio
16.10.4 Recent News
16.11 Akero Therapeutics, Inc.
16.11.1 Company Snapshot
16.11.2 Revenue Analysis
16.11.3 Pipeline Product Portfolio
16.11.4 Recent Development
16.12 Bristol-myers Squibb
16.12.1 Company Snapshot
16.12.2 Revenue Analysis
16.12.3 Product Portfolio
16.12.4 Recent Development
16.13 Calliditas Therapeutics Ab
16.13.1 Company Snapshot
16.13.2 Pipeline Product Portfolio
16.13.3 Recent Development
16.14 Curevac Se
16.14.1 Company Snapshot
16.14.2 Revenue Analysis
16.14.3 Product Portfolio
16.14.4 Recent Development
16.15 Conatuspharma
16.15.1 Company Snapshot
16.15.2 Product Portfolio
16.15.3 Recent Development/News
16.16 Enanta Pharmaceuticals, Inc.
16.16.1 Company Snapshot
16.16.2 Revenue Analysis
16.16.3 Product Portfolio
16.16.4 Recent Development
16.17 Echosens
16.17.1 Company Snapshot
16.17.2 Product Portfolio
16.17.3 Recent Development/News
16.18 F. Hoffmann-la Roche Ltd
16.18.1 Company Snapshot
16.18.2 Revenue Analysis
16.18.3 Company Share Analysis
16.18.4 Product Portfolio
16.18.5 Recent Development
16.19 Galecto Biotech
16.19.1 Company Snapshot
16.19.2 Revenue Analysis
16.19.3 Pipeline Product Portfolio
16.19.4 Recent Development/News
16.20 Galectin Therapeutics, Inc.
16.20.1 Company Snapshots
16.20.2 Revenue Analysis And Segmental Analysis
16.20.3 Pipeline Product Portfolio
16.20.4 Recent Development
16.21 Gyre Therapeutics, Inc.
16.21.1 Company Snapshot
16.21.2 Revenue Analysis And Segmented Analysis
16.21.3 Product Portfolio
16.21.4 Recent Development/News
16.22 Genfit Sa
16.22.1 Company Snapshots
16.22.2 Revenue Analysis And Segmented Analysis
16.22.3 Pipeline Product Portfolio
16.22.4 Recent Development
16.23 Hepion Pharmaceuticals
16.23.1 Company Snapshot
16.23.2 Revenue Analysis
16.23.3 Pipeline Portfolio
16.23.4 Recent Development
16.24 Ipsen Pharma
16.24.1 Company Snapshot
16.24.2 Revenue Analysis
16.24.3 Pipeline Product Portfolio
16.24.4 Recent News/Developments
16.25 La Renon Healthcare Pvt. Ltd.
16.25.1 Company Snapshot
16.25.2 Product Portfolio
16.25.3 Recent Development
16.26 Madrigal Pharmaceuticals
16.26.1 Company Snapshots
16.26.2 Revenue Analysis And Segmented Analysis
16.26.3 Product Portfolio
16.26.4 Recent Development
16.27 Novo Nordisk A/S
16.27.1 Company Snapshot
16.27.2 Revenue Analysis
16.27.3 Pipeline Product Portfolio
16.27.4 Recent Development
16.28 Novomedix
16.28.1 Company Snapshot
16.28.2 Pipeline Product Portfolio
16.28.3 Recent Development
16.29 Pilant Therapeutics, Inc.
16.29.1 Company Snapshot
16.29.2 Revenue Analysis
16.29.3 Pipeline Product Portfolio
16.29.4 Recent News
16.30 Pfizer Inc.
16.30.1 Company Snapshot
16.30.2 Revenue Analysis
16.30.3 Pipeline Product Portfolio
16.30.4 Recent Development/News
16.31 Sagimet Biosciences
16.31.1 Company Snapshots
16.31.2 Revenue Analysis
16.31.3 1.1.4 Product Portfolio
16.31.4 Recent Development/News
16.32 Takeda Pharmaceutical Company Limited
16.32.1 Company Snapshot
16.32.2 Revenue Analysis
16.32.3 Pipeline Product Portfolio
16.32.4 Product Portfolio
16.32.5 Recent Development
16.33 Tvardi Therapeutics
16.33.1 Company Snapshot
16.33.2 Pipeline Product Portfolio
16.33.3 Recent Development/News
16.34 Vertex Pharmaceuticals Incorporated
16.34.1 Company Snapshot
16.34.2 Revenue Analysis
16.34.3 Product Portfolio
16.34.4 Recent Development
16.35 Viking Therapeutics
16.35.1 Company Snapshot
16.35.2 Revenue Analysis
16.35.3 Pipeline Product Portfolio
16.35.4 Recent Development
17 Questionnaire
18 Related Reports
List Of Tables
Table 1 Global Incidence Of Cirrhosis By Gender (2019)
Table 2 Treatment Adherence Levels In Liver Disease Patients
Table 3 Global Liver Fibrosis Treatment Market, By Treatment Type, 2018-2032 (Usd Thousand)
Table 4 Global Medication In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 5 Global Medication In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 6 Global Medication In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 7 Global Antiviral Agents In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 8 Global Antiviral Agents In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 9 Global Antiviral Agents In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Asp In Usd/Units)
Table 10 Global Antifibrotic Agents In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 11 Global Antifibrotic Agents In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 12 Global Antifibrotic Agents In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Asp In Usd/Units)
Table 13 Global Anti-inflammatory Drugs In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 14 Global Corticosteroids In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 15 Global Corticosteroids In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 16 Global Corticosteroids In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Asp In Usd/Units)
Table 17 Global Tumor Necrosis Factor (Tnf) Inhibitors In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 18 Global Tumor Necrosis Factor (Tnf) Inhibitors In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 19 Global Tumor Necrosis Factor (Tnf) Inhibitors In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Asp In Usd/Units)
Table 20 Global Interleukin (Il) Inhibitors In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 21 Global Interleukin (Il) Inhibitor In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 22 Global Interleukin (Il) Inhibitor In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Asp In Usd/Units)
Table 23 Global Anti-inflammatory Drugs In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 24 Global Immunosuppressants In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 25 Global Immunosuppressants In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 26 Global Immunosuppressants In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Asp In Usd/Units)
Table 27 Global Medication In Liver Fibrosis Treatment Market, By Drug Status, 2018-2032 (Usd Thousand)
Table 28 Global Marketed Drugs In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 29 Global Medication In Liver Fibrosis Treatment Market, By Drug Type, 2018-2032 (Usd Thousand)
Table 30 Global Branded Drugs In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 31 Global Medication In Liver Fibrosis Treatment Market, By Route Of Administration, 2018-2032 (Usd Thousand)
Table 32 Global Surgery/Therapy In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 33 Global Surgery/Therapy In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 34 Global Liver Transplantation In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 35 Global Endoscopic & Minimally Invasive Procedures In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 36 Global Liver Ablation Procedures In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 37 Global Partial Hepatectomy (Liver Resection) In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 38 Global Cell-based Therapy In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 39 Global Stem Cell Therapy In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 40 Global Gene Therapy In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 41 Global Hepatocyte Apoptosis Inhibitors In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 42 Global Liver Fibrosis Treatment Market, By Stages, 2018-2032 (Usd Thousand)
Table 43 Global F2 In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 44 Global F1 In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 45 Global F3 In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 46 Global F4 In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 47 Global Liver Fibrosis Treatment Market, By Indication, 2018-2032 (Usd Thousand)
Table 48 Global Non-alcoholic Steatohepatitis (Nash) In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 49 Global Hepatitis B & C-induced Fibrosis In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 50 Global Hepatitis B & C-induced Fibrosis In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 51 Global Alcoholic Liver Disease (Ald) In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 52 Global Autoimmune Liver Diseases In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 53 Global Autoimmune Liver Diseases In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 54 Global Genetic Disorders In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 55 Global Genetic Disorders In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 56 Global Others In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 57 Global Liver Fibrosis Treatment Market, By Gender, 2018-2032 (Usd Thousand)
Table 58 Global Male In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 59 Global Male In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 60 Global Female In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 61 Global Female In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 62 Global Liver Fibrosis Treatment Market, By End User, 2018-2032 (Usd Thousand)
Table 63 Global Hospitals In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 64 Global Hospitals In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 65 Global Specialty Clinics In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 66 Global Specialty Clinics In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 67 Global Clinics In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 68 Global Ambulatory And Research Centers In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 69 Global Others In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 70 Global Liver Fibrosis Treatment Market, By Distribution Channel, 2018-2032 (Usd Thousand)
Table 71 Global Direct Tender In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 72 Global Retail Sales In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 73 Global Retail Sales In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 74 Global Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 75 North America Liver Fibrosis Treatment Market, By Country, 2018-2032 (Usd Thousand)
Table 76 North America Liver Fibrosis Treatment Market, By Treatment Type, 2018-2032 (Usd Thousand)
Table 77 North America Medication In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 78 North America Medication In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 79 North America Antiviral Agents In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 80 North America Antiviral Agents In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 81 North America Antiviral Agents In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Asp In Usd/Units)
Table 82 North America Antifibrotic Agents In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 83 North America Antifibrotic Agents In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 84 North America Antifibrotic Agents In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Asp In Usd/Units)
Table 85 North America Anti-inflammatory Drugs In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 86 North America Anti-inflammatory Drugs In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 87 North America Corticosteroids In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 88 North America Corticosteroids In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 89 North America Corticosteroids In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Asp In Usd/Units)
Table 90 North America Tumor Necrosis Factor (Tnf) Inhibitors In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 91 North America Tumor Necrosis Factor (Tnf) Inhibitors In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 92 North America Tumor Necrosis Factor (Tnf) Inhibitors In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Asp In Usd/Units)
Table 93 North America Interleukin (Il) Inhibitors In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 94 North America Interleukin (Il) Inhibitor In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 95 North America Interleukin (Il) Inhibitor In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Asp In Usd/Units)
Table 96 North America Immunosuppressants In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 97 North America Immunosuppressants In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 98 North America Immunosuppressants In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Asp In Usd/Units)
Table 99 North America Medication In Liver Fibrosis Treatment Market, By Drug Status, 2018-2032 (Usd Thousand)
Table 100 North America Marketed Drugs In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 101 North America Medication In Liver Fibrosis Treatment Market, By Drug Type, 2018-2032 (Usd Thousand)
Table 102 North America Branded Drugs In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 103 North America Medication In Liver Fibrosis Treatment Market, By Route Of Administration, 2018-2032 (Usd Thousand)
Table 104 North America Surgery/Therapy In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 105 North America Liver Transplantation In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 106 North America Endoscopic & Minimally Invasive Procedures In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 107 North America Liver Ablation Procedures In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 108 North America Partial Hepatectomy (Liver Resection) In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 109 North America Cell-based Therapy In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 110 North America Stem Cell Therapy In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 111 North America Gene Therapy In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 112 North America Hepatocyte Apoptosis Inhibitors In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 113 North America Liver Fibrosis Treatment Market, By Stages, 2018-2032 (Usd Thousand)
Table 114 North America Liver Fibrosis Treatment Market, By Indication, 2018-2032 (Usd Thousand)
Table 115 North America Hepatitis B & C-induced Fibrosis In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 116 North America Autoimmune Liver Diseases In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 117 North America Genetic Disorders In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 118 North America Liver Fibrosis Treatment Market, By Gender, 2018-2032 (Usd Thousand)
Table 119 North America Male In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 120 North America Female In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 121 North America Liver Fibrosis Treatment Market, By End User, 2018-2032 (Usd Thousand)
Table 122 North America Hospitals In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 123 North America Specialty Clinics In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 124 North America Liver Fibrosis Treatment Market, By Distribution Channel, 2018-2032 (Usd Thousand)
Table 125 North America Retail Sales In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 126 U.S. Liver Fibrosis Treatment Market, By Treatment Type, 2018-2032 (Usd Thousand)
Table 127 U.S. Medication In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 128 U.S. Medication In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 129 U.S. Antiviral Agents In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 130 U.S. Antiviral Agents In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 131 U.S. Antiviral Agents In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Asp In Usd/Units)
Table 132 U.S. Antifibrotic Agents In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 133 U.S. Antifibrotic Agents In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 134 U.S. Antifibrotic Agents In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Asp In Usd/Units)
Table 135 U.S. Anti-inflammatory Drugs In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 136 U.S. Anti-inflammatory Drugs In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 137 U.S. Corticosteroids In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 138 U.S. Corticosteroids In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 139 U.S. Corticosteroids In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Asp In Usd/Units)
Table 140 U.S. Tumor Necrosis Factor (Tnf) Inhibitors In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 141 U.S. Tumor Necrosis Factor (Tnf) Inhibitors In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 142 U.S. Tumor Necrosis Factor (Tnf) Inhibitors In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Asp In Usd/Units)
Table 143 U.S. Interleukin (Il) Inhibitors In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 144 U.S. Interleukin (Il) Inhibitor In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 145 U.S. Interleukin (Il) Inhibitor In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Asp In Usd/Units)
Table 146 U.S. Immunosuppressants In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 147 U.S. Immunosuppressants In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 148 U.S. Immunosuppressants In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Asp In Usd/Units)
Table 149 U.S. Medication In Liver Fibrosis Treatment Market, By Drug Status, 2018-2032 (Usd Thousand)
List Of Figures
Figure 1 Asia-pacific Liver Fibrosis Treatment Market: Segmentation
Figure 2 Asia-pacific Liver Fibrosis Treatment Market: Data Triangulation
Figure 3 Asia-pacific Liver Fibrosis Treatment Market: Droc Analysis
Figure 4 Asia-pacific Liver Fibrosis Treatment Market: Regional Market Analysis
Figure 5 Asia-pacific Liver Fibrosis Treatment Market: Company Research Analysis
Figure 6 Asia-pacific Liver Fibrosis Treatment Market: Interview Demographics
Figure 7 Asia-pacific Liver Fibrosis Treatment Market: Dbmr Market Position Grid
Figure 8 Asia-pacific Liver Fibrosis Treatment Market: Market End User Coverage Grid
Figure 9 Asia-pacific Liver Fibrosis Treatment Market: Vendor Share Analysis
Figure 10 Asia-pacific Liver Fibrosis Treatment Market: Segmentation
Figure 11 Increasing Prevalence Of Liver Diseases Is Expected To Drive The Growth Of Asia-p

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us